{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:48:39Z","timestamp":1790707719811,"version":"4.1.0"},"reference-count":67,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Patients with the autoimmune polyendocrine syndrome type I (APS-I), caused by mutations in the autoimmune regulator (AIRE) gene, and myasthenia gravis (MG) with thymoma, show intriguing but unexplained parallels. They include uncommon manifestations like autoimmune adrenal insufficiency (AI), hypoparathyroidism, and chronic mucocutaneous candidiasis plus autoantibodies neutralizing IL-17, IL-22, and type I IFNs. Thymopoiesis in the absence of AIRE is implicated in both syndromes. To test whether these parallels extend further, we screened 247 patients with MG, thymoma, or both for clinical features and organ-specific autoantibodies characteristic of APS-I patients, and we assayed 26 thymoma samples for transcripts for AIRE and 16 peripheral tissue-specific autoantigens (TSAgs) by quantitative PCR. We found APS-I\u2013typical autoantibodies and clinical manifestations, including chronic mucocutaneous candidiasis, AI, and asplenia, respectively, in 49 of 121 (40%) and 10 of 121 (8%) thymoma patients, but clinical features seldom occurred together with the corresponding autoantibodies. Both were rare in other MG subgroups (n = 126). In 38 patients with APS-I, by contrast, we observed neither autoantibodies against muscle Ags nor any neuromuscular disorders. Whereas relative transcript levels for AIRE and 7 of 16 TSAgs showed the expected underexpression in thymomas, levels were increased for four of the five TSAgs most frequently targeted by these patients\u2019 autoantibodies. Therefore, the clinical and serologic parallels to APS-I in patients with thymomas are not explained purely by deficient TSAg transcription in these aberrant AIRE-deficient tumors. We therefore propose additional explanations for the unusual autoimmune biases they provoke. Thymoma patients should be monitored for potentially life-threatening APS-I manifestations such as AI and hypoparathyroidism.<\/jats:p>","DOI":"10.4049\/jimmunol.1401068","type":"journal-article","created":{"date-parts":[[2014,9,18]],"date-time":"2014-09-18T06:45:32Z","timestamp":1411022732000},"page":"3880-3890","source":"Crossref","is-referenced-by-count":59,"title":["Clinical and Serologic Parallels to APS-I in Patients with Thymomas and Autoantigen Transcripts in Their Tumors"],"prefix":"10.1093","volume":"193","author":[{"given":"Anette S B","family":"Wolff","sequence":"first","affiliation":[{"name":"Department of Clinical Science, University of Bergen , 5021 Bergen ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaanika","family":"K\u00e4rner","sequence":"additional","affiliation":[{"name":"Molecular Pathology Group, Institute of Biomedicine and Translational Medicine, University of Tartu , 50090 Tartu ,","place":["Estonia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jone F","family":"Owe","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, University of Bergen , 5021 Bergen ,","place":["Norway"]},{"name":"Department of Neurology, Haukeland University Hospital , 5021 Bergen ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bergithe E V","family":"Oftedal","sequence":"additional","affiliation":[{"name":"Department of Clinical Science, University of Bergen , 5021 Bergen ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils Erik","family":"Gilhus","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, University of Bergen , 5021 Bergen ,","place":["Norway"]},{"name":"Department of Neurology, Haukeland University Hospital , 5021 Bergen ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina M","family":"Erichsen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Haukeland University Hospital , 5021 Bergen ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olle","family":"K\u00e4mpe","sequence":"additional","affiliation":[{"name":"Department of Medicine, Solna, Karolinska University Hospital, Karolinska Institutet , SE-171 76 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Meager","sequence":"additional","affiliation":[{"name":"Biotherapeutics Group, The National Institute for Biological Standards and Control , South Mimms, Potters Bar, Hertfordshire EN6 3QG ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4rt","family":"Peterson","sequence":"additional","affiliation":[{"name":"Molecular Pathology Group, Institute of Biomedicine and Translational Medicine, University of Tartu , 50090 Tartu ,","place":["Estonia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Kisand","sequence":"additional","affiliation":[{"name":"Molecular Pathology Group, Institute of Biomedicine and Translational Medicine, University of Tartu , 50090 Tartu ,","place":["Estonia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Willcox","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurology, Weatherall Institute for Molecular Medicine, University of Oxford , Oxford OX3 9DU ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eystein S","family":"Husebye","sequence":"additional","affiliation":[{"name":"Department of Clinical Science, University of Bergen , 5021 Bergen ,","place":["Norway"]},{"name":"Department of Medicine, Haukeland University Hospital , 5021 Bergen ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,10,15]]},"reference":[{"key":"2025030707405069700_r1","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/ng1297-399","article-title":"An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains","volume":"17","author":"Finnish-German APECED Consortium","year":"1997","journal-title":"Nat. Genet."},{"key":"2025030707405069700_r2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/ng1297-393","article-title":"Positional cloning of the APECED gene","volume":"17","author":"Nagamine","year":"1997","journal-title":"Nat. Genet."},{"key":"2025030707405069700_r3","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1126\/science.1075958","article-title":"Projection of an immunological self shadow within the thymus by the aire protein","volume":"298","author":"Anderson","year":"2002","journal-title":"Science"},{"key":"2025030707405069700_r4","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1365-2796.2009.02090.x","article-title":"Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I","volume":"265","author":"Husebye","year":"2009","journal-title":"J. Intern. Med."},{"key":"2025030707405069700_r5","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1210\/jc.2005-2611","article-title":"Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy","volume":"91","author":"Perheentupa","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2025030707405069700_r6","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa0706487","article-title":"Autoimmune polyendocrine syndrome type 1 and NALP5, a parathyroid autoantigen","volume":"358","author":"Alimohammadi","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"2025030707405069700_r7","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1210\/jc.2003-030279","article-title":"Prevalence and clinical associations of 10 defined autoantibodies in autoimmune polyendocrine syndrome type I","volume":"89","author":"S\u00f6derbergh","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2025030707405069700_r8","first-page":"460","article-title":"Autoantibodies against aromatic L-amino acid decarboxylase identifies a subgroup of patients with Addison\u2019s disease","volume":"85","author":"S\u00f6derbergh","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2025030707405069700_r9","first-page":"1717","article-title":"Identification of the main gonadal autoantigens in patients with adrenal insufficiency and associated ovarian failure","volume":"80","author":"Winqvist","year":"1995","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2025030707405069700_r10","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/0140-6736(92)91829-W","article-title":"21-Hydroxylase, a major autoantigen in idiopathic Addison\u2019s disease","volume":"339","author":"Winqvist","year":"1992","journal-title":"Lancet"},{"key":"2025030707405069700_r11","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1371\/journal.pmed.0030289","article-title":"Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1","volume":"3","author":"Meager","year":"2006","journal-title":"PLoS Med."},{"key":"2025030707405069700_r12","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1210\/jc.2008-0935","article-title":"Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I","volume":"93","author":"Meloni","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2025030707405069700_r13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.clim.2008.07.002","article-title":"Radioimmunoassay for autoantibodies against interferon omega; its use in the diagnosis of autoimmune polyendocrine syndrome type I","volume":"129","author":"Oftedal","year":"2008","journal-title":"Clin. Immunol."},{"key":"2025030707405069700_r14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1084\/jem.20091669","article-title":"Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines","volume":"207","author":"Kisand","year":"2010","journal-title":"J. Exp. Med."},{"key":"2025030707405069700_r15","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1084\/jem.20091983","article-title":"Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I","volume":"207","author":"Puel","year":"2010","journal-title":"J. Exp. Med."},{"key":"2025030707405069700_r16","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2249.1990.tb05440.x","article-title":"Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin","volume":"82","author":"Aarli","year":"1990","journal-title":"Clin. Exp. Immunol."},{"key":"2025030707405069700_r17","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3109\/08916930903555935","article-title":"Thymoma and paraneoplastic myasthenia gravis","volume":"43","author":"Marx","year":"2010","journal-title":"Autoimmunity"},{"key":"2025030707405069700_r18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1600-0404.2006.00608.x","article-title":"Titin and ryanodine receptor antibodies in myasthenia gravis","volume":"183","author":"Skeie","year":"2006","journal-title":"Acta Neurol. Scand. Suppl."},{"key":"2025030707405069700_r19","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3109\/08916930903518073","article-title":"The auto-antigen repertoire in myasthenia gravis","volume":"43","author":"Vrolix","year":"2010","journal-title":"Autoimmunity"},{"key":"2025030707405069700_r20","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s004150050059","article-title":"Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients","volume":"244","author":"Beekman","year":"1997","journal-title":"J. Neurol."},{"key":"2025030707405069700_r21","first-page":"669","article-title":"Acquired aplastic anemia: correlation between etiology, pathophysiology, bone marrow histology and prognosis factors","volume":"50","author":"Gaman","year":"2009","journal-title":"Rom. J. Morphol. Embryol."},{"key":"2025030707405069700_r22","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1749-6632.1976.tb47708.x","article-title":"HL-A antigens, autoantibody production, and associated diseases in thymoma patients, with and without myasthenia gravis","volume":"274","author":"Oosterhuis","year":"1976","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"2025030707405069700_r23","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/archinte.1974.00320200184029","article-title":"The spectrum of diseases associated with thymoma. Coincidence or syndrome?","volume":"134","author":"Souadjian","year":"1974","journal-title":"Arch. Intern. Med."},{"key":"2025030707405069700_r24","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s10875-011-9617-4","article-title":"Radioligand-binding assay reveals distinct autoantibody preferences for type I interferons in APS I and myasthenia gravis subgroups","volume":"32","author":"Hapnes","year":"2012","journal-title":"J. Clin. Immunol."},{"key":"2025030707405069700_r25","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1046\/j.1365-2249.2003.02113.x","article-title":"Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and\/or myasthenia gravis","volume":"132","author":"Meager","year":"2003","journal-title":"Clin. Exp. Immunol."},{"key":"2025030707405069700_r26","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/cei.12024","article-title":"Anti-cytokine autoantibodies suggest pathogenetic links with autoimmune regulator deficiency in humans and mice","volume":"171","author":"K\u00e4rner","year":"2013","journal-title":"Clin. Exp. Immunol."},{"key":"2025030707405069700_r27","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJMc0909510","article-title":"Acquired autoimmune polyglandular syndrome, thymoma, and an AIRE defect","volume":"362","author":"Cheng","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"2025030707405069700_r28","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/BF01488718","article-title":"Myasthenia gravis: overlap with \u2018polyendocrine\u2019 autoimmunity","volume":"61","author":"Scherbaum","year":"1983","journal-title":"Klin. Wochenschr."},{"key":"2025030707405069700_r29","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3816\/CLC.2009.n.051","article-title":"Myasthenia gravis and autoimmune Addison disease in a patient with thymoma","volume":"10","author":"Seker","year":"2009","journal-title":"Clin. Lung Cancer"},{"key":"2025030707405069700_r30","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jns.2011.05.038","article-title":"Multiple paraneoplastic syndromes: myasthenia gravis, vitiligo, alopecia areata, and oral lichen planus associated with thymoma","volume":"308","author":"Qiao","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"2025030707405069700_r31","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1365-2249.2007.03442.x","article-title":"Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas","volume":"149","author":"Scarpino","year":"2007","journal-title":"Clin. Exp. Immunol."},{"key":"2025030707405069700_r32","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/path.2141","article-title":"Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1)","volume":"211","author":"Str\u00f6bel","year":"2007","journal-title":"J. Pathol."},{"key":"2025030707405069700_r33","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/eji.201041253","article-title":"Mucocutaneous candidiasis and autoimmunity against cytokines in APECED and thymoma patients: clinical and pathogenetic implications","volume":"41","author":"Kisand","year":"2011","journal-title":"Eur. J. Immunol."},{"key":"2025030707405069700_r34","first-page":"447","article-title":"Myasthenic and nonmyasthenic thymoma. An expansion of a minor cortical epithelial cell subset?","volume":"127","author":"Willcox","year":"1987","journal-title":"Am. J. Pathol."},{"key":"2025030707405069700_r35","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1210\/jc.2006-1873","article-title":"Autoimmune polyendocrine syndrome type 1 in Norway: phenotypic variation, autoantibodies, and novel mutations in the autoimmune regulator gene","volume":"92","author":"Wolff","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2025030707405069700_r36","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1440-1827.1997.tb03715.x","article-title":"Cytokeratin expression in normal human thymus at different ages","volume":"47","author":"Masunaga","year":"1997","journal-title":"Pathol. Int."},{"key":"2025030707405069700_r37","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/BF00300707","article-title":"Cytokeratin expression in human thymus: immunohistochemical mapping","volume":"279","author":"Shezen","year":"1995","journal-title":"Cell Tissue Res."},{"key":"2025030707405069700_r38","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1196\/annals.1405.021","article-title":"Autoimmunizing mechanisms in thymoma and thymus","volume":"1132","author":"Willcox","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"2025030707405069700_r39","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1093\/rheumatology\/39.9.1044","article-title":"Thymoma-associated systemic lupus erythematosus, exacerbating after thymectomy. A case report and review of the literature","volume":"39","author":"Boonen","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"2025030707405069700_r40","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.humimm.2013.06.020","article-title":"Autoimmune associations and autoantibody screening show focused recognition in patient subgroups with generalized myasthenia gravis","volume":"74","author":"Klein","year":"2013","journal-title":"Hum. Immunol."},{"key":"2025030707405069700_r41","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1210\/jc.2009-1368","article-title":"Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry","volume":"94","author":"Erichsen","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2025030707405069700_r42","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1530\/EJE-10-1206","article-title":"Hypoparathyroidism and autoimmunity in the 22q11.2 deletion syndrome","volume":"165","author":"Lima","year":"2011","journal-title":"Eur. J. Endocrinol."},{"key":"2025030707405069700_r43","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1182\/blood-2010-02-267583","article-title":"Hypomorphic Rag mutations can cause destructive midline granulomatous disease","volume":"116","author":"De Ravin","year":"2010","journal-title":"Blood"},{"key":"2025030707405069700_r44","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jaci.2013.11.038","article-title":"Autoimmunity due to RAG deficiency and estimated disease incidence in RAG1\/2 mutations","volume":"133","author":"Chen","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"2025030707405069700_r45","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1210\/jc.2009-1115","article-title":"T cell responses to steroid cytochrome P450 21-hydroxylase in patients with autoimmune primary adrenal insufficiency","volume":"94","author":"Bratland","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2025030707405069700_r46","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1006\/bbrc.1999.1945","article-title":"Identification of tyrosine hydroxylase as an autoantigen in autoimmune polyendocrine syndrome type I","volume":"267","author":"Hedstrand","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2025030707405069700_r47","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1084\/jem.20090300","article-title":"Neonatal tolerance revisited: a perinatal window for Aire control of autoimmunity","volume":"206","author":"Guerau-de-Arellano","year":"2009","journal-title":"J. Exp. Med."},{"key":"2025030707405069700_r48","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1126\/science.1159407","article-title":"Deletional tolerance mediated by extrathymic Aire-expressing cells","volume":"321","author":"Gardner","year":"2008","journal-title":"Science"},{"key":"2025030707405069700_r49","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.immuni.2013.08.005","article-title":"Extrathymic Aire-expressing cells are a distinct bone marrow-derived population that induce functional inactivation of CD4\u207a T cells","volume":"39","author":"Gardner","year":"2013","journal-title":"Immunity"},{"key":"2025030707405069700_r50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nri2136-c1","article-title":"Does the deficiency of Aire in mice really resemble human APECED?","volume":"7","author":"Kek\u00e4l\u00e4inen","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"2025030707405069700_r51","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/ana.20340","article-title":"Selective loss of regulatory T cells in thymomas","volume":"56","author":"Str\u00f6bel","year":"2004","journal-title":"Ann. Neurol."},{"key":"2025030707405069700_r52","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3389\/fimmu.2012.00019","article-title":"Post-Aire maturation of thymic medullary epithelial cells involves selective expression of keratinocyte-specific autoantigens","volume":"3","author":"Wang","year":"2012","journal-title":"Front. Immunol."},{"key":"2025030707405069700_r53","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.4049\/jimmunol.178.2.1208","article-title":"A defect of regulatory T cells in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy","volume":"178","author":"Kek\u00e4l\u00e4inen","year":"2007","journal-title":"J. Immunol."},{"key":"2025030707405069700_r54","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jaut.2010.07.008","article-title":"Regulatory T cell defect in APECED patients is associated with loss of naive FOXP3(+) precursors and impaired activated population","volume":"35","author":"Laakso","year":"2010","journal-title":"J. Autoimmun."},{"key":"2025030707405069700_r55","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.jaci.2005.08.036","article-title":"CD4+CD25+ T-regulatory cells are decreased in patients with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy","volume":"116","author":"Ryan","year":"2005","journal-title":"J. Allergy Clin. Immunol."},{"key":"2025030707405069700_r56","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1365-3083.2010.02397.x","article-title":"Flow cytometry study of blood cell subtypes reflects autoimmune and inflammatory processes in autoimmune polyendocrine syndrome type I","volume":"71","author":"Wolff","year":"2010","journal-title":"Scand. J. Immunol."},{"key":"2025030707405069700_r57","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1146\/annurev.immunol.23.021704.115601","article-title":"A central role for central tolerance","volume":"24","author":"Kyewski","year":"2006","journal-title":"Annu. Rev. Immunol."},{"key":"2025030707405069700_r58","first-page":"3708","article-title":"Correlating genetic aberrations with World Health Organization-defined histology and stage across the spectrum of thymomas","volume":"63","author":"Inoue","year":"2003","journal-title":"Cancer Res."},{"key":"2025030707405069700_r59","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.coi.2010.08.003","article-title":"How thymic antigen presenting cells sample the body\u2019s self-antigens","volume":"22","author":"Derbinski","year":"2010","journal-title":"Curr. Opin. Immunol."},{"key":"2025030707405069700_r60","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/eji.200636962","article-title":"Highly variable expression of tissue-restricted self-antigens in human thymus: implications for self-tolerance and autoimmunity","volume":"37","author":"Taubert","year":"2007","journal-title":"Eur. J. Immunol."},{"key":"2025030707405069700_r61","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/nature06066","article-title":"An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus","volume":"448","author":"Giraud","year":"2007","journal-title":"Nature"},{"key":"2025030707405069700_r62","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jneuroim.2008.06.016","article-title":"Preferential expression of AChR epsilon-subunit in thymomas from patients with myasthenia gravis","volume":"201-202","author":"Maclennan","year":"2008","journal-title":"J. Neuroimmunol."},{"key":"2025030707405069700_r63","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12026-008-8083-4","article-title":"Characterization of cultured thymus tissue used for transplantation with emphasis on promiscuous expression of thyroid tissue-specific genes","volume":"44","author":"Li","year":"2009","journal-title":"Immunol. Res."},{"key":"2025030707405069700_r64","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1096\/fasebj.13.8.893","article-title":"Paracrine glucocorticoid activity produced by mouse thymic epithelial cells","volume":"13","author":"Pazirandeh","year":"1999","journal-title":"FASEB J."},{"key":"2025030707405069700_r65","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s10875-013-9938-6","article-title":"Anti-cytokine autoantibodies preceding onset of autoimmune polyendocrine syndrome type I features in early childhood","volume":"33","author":"Wolff","year":"2013","journal-title":"J. Clin. Immunol."},{"key":"2025030707405069700_r66","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3389\/fimmu.2013.00313","article-title":"Human APECED; a Sick Thymus Syndrome?","volume":"4","author":"Arstila","year":"2013","journal-title":"Front. Immunol."},{"key":"2025030707405069700_r67","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2265.1982.tb00726.x","article-title":"Development of adrenocortical failure in non-Addisonian patients with antibodies to adrenal cortex. A clinical follow-up study","volume":"16","author":"Scherbaum","year":"1982","journal-title":"Clin. Endocrinol. (Oxf.)"}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/193\/8\/3880\/62228502\/1401068.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/193\/8\/3880\/62228502\/1401068.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T08:11:25Z","timestamp":1741335085000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/193\/8\/3880\/7960422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":67,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,10,15]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1401068","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,10]]},"published":{"date-parts":[[2014,10]]}}}